A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH

NCT04084678 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

PAH
Pulmonary Hypertension
Hypertension
Connective Tissue Disease
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Disease
Pulmonary Arterial Hypertension

Interventions

DRUG: Ralinepag
DRUG: Placebo

Sponsor

United Therapeutics